ZYBERNO
Stock Report
Updated Sep 2, 2026

Lyra Therapeutics, Inc. (LYRA)

Healthcare • OTC

$0.20

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
15.0/100
POOR BUSINESS
Lyra Therapeutics, Inc. (LYRA) scores 15/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-7,794.5%)
Return on Capital (Capital Efficiency):CRITICAL (-637.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Lyra Therapeutics, Inc. (LYRA) stock report — Zyberno Score 15/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, LYRA generated -$31.66M in Owner Earnings. Reinvestment rate: 1.5%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.20
Market Cap:$8.87M

Valuation Multiples (2)

P/S Ratio:22.30x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$23.24M

Price Action & Momentum (1)

% of 52-Week High:2.3%
B. Profitability Assessment

Return Metrics (4)

ROA:-61.3%
Reinvestment Rate:1.5%
Fundamental Growth Rate (g):-9.4%

Margin Analysis (3)

Operating Margin Ttm:-7,794.5%
Net Margin Ttm:-7,266.1%
Ebitda Margin:-7,679.1%

TTM Performance (2)

Operating Margin Ttm:-7,794.5%
Net Margin Ttm:-7,266.1%

Yield Metrics (2)

Earnings Yield:-$186.20K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-1,992.6%
Latest Earnings Filed:2026-03-31

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-41.9%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.71x
Quick Ratio:1.71x
Cash Ratio:1.67x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:6,750,000.00
Cash And Cash Equivalents:15,893,000.00
Long Term Debt:$25.44M
Net Debt:$14.37M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $398.00K
Linear Growth: -41.9%
📊 Click to view full LYRA Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$31.02M

Bottom Line Performance (3)

-$28.92M
Income Before Tax:-$28.91M
Ebitda Ttm:-30,563,000.00

Operating Expenses (5)

Operating Expenses:31,420,000.00
R And D Expense:18,411,000.00
Sga Expense:11,540,000.00
Income Tax Expense:$11.00K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:263,014.3%
Sga To Revenue Percentage:164,857.1%
Ebitda Margin:-7,679.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$36.11M
Current Assets:$16.27M
Ppe Net:5,600,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:46,825,000.00
Current Liabilities:9,522,000.00
Long Term Debt:$25.44M
Short Term Debt:$4.82M

Equity & Capital (3)

Equity:-$10.72M
Retained Earnings:-$433.71M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:663,000.00

Special Items (2)

Contract Liabilities:11,862,000.00
Stock Based Compensation:562,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$28.86M-$33.65M

Investment Activities (1)

Investing Cash Flow:-$96.00K

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:459,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-18.62
-$18.62
Earnings Per Share Ttm:-$0.65

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.01
Operating Cash Flow Per Share:-$0.65

Book Value & Capital (2)

Book Value Per Share:-$0.24
Cash Per Share:0.36

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x
Working Capital Turnover Ttm:0.06x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:608.03
Cash Conversion Cycle:-2,606.03
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$31.66M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.5%
Fundamental Growth Rate (g):-9.4%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-41.9%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-48.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:LYRA
Company Name:Lyra Therapeutics, Inc.
Sector:Healthcare
Industry:Medical Devices
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:44.37M
Shares Outstanding Basic:1.55M
Shares Outstanding Diluted:1.55M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-02 05:36:36 UTC
Data Timestamp:2026-08-24T16:40:12.219968
Scroll to Top